http://www.rns-pdf.londonstockexchange.com/rns/5385D_1-2022-10-20.pdf

This Notice is sent to you as a shareholder of the MS Scientific Beta US Equity Factors UCITS ETF,a sub-fund of FundLogic Alternatives plc. It is important and requires your immediate attention. If you are in any doubt as to the action to be taken, you should immediately consult your stockbroker, solicitor or attorney or other professional advisor. If you sold or otherwise transferred your holding in the MS Scientific Beta US Equity Factors UCITS ETF, please send this Notice to the stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

This Notice has not been reviewed by the Central Bank of Ireland and it is possible that changes hereto may be necessary to meet the requirements of the Central Bank of Ireland. The Directors are of the opinion that there is nothing contained in this Notice nor in the proposals detailed herein that conflicts with the regulations of the Central Bank of Ireland.

Defined terms have the same meaning as described in the Company's prospectus dated 1 August 2022, as amended (the "Prospectus") and the supplement in respect of the Fund dated 1 August 2022 (the "Supplement").

FundLogic Alternatives plc 70 Sir John Rogerson's Quay Dublin 2

Ireland

(an umbrella fund with segregated liability between sub-funds)

20 October 2022

FundLogic Alternatives plc (the "Company")

MS Scientific Beta US Equity Factors UCITS ETF (the "Fund")

Dear Shareholder

As a Shareholder in the Fund, we are writing to inform you that the Directors have resolved to terminate the Fund, with effect from 17 November 2022 (the "Effective Date").

This decision has been taken because the Fund's value is below the minimum level detailed in the Prospectus, namely US$50,000,000.

Shareholders may, in accordance with the conditions set out in the Prospectus and the Supplement, redeem their shares in the Fund on each Dealing Day prior to the Effective Date. Any remaining Shareholders will have their shares in the Fund redeemed at the applicable Net Asset Value per Share on the Effective Date. The Fund may commence to liquidate its exposure prior to the Effective Date and accordingly the Fund's exposure may substantially, and increasingly as the Effective Date approaches, consist of cash. Please note that the trading of Shares on the secondary market will continue until the Effective Date or the date at which all Shares are voluntarily redeemed prior to the Effective Date.

Directors: Maurice Murphy, Simon O'Sullivan, Rowena Mallaghan (UK) and David Haydon (UK) Registered Office: 70 Sir John Rogerson's Quay, Dublin 2, Ireland

Companies Registration Office Number 483770